News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Shares Feel the Pain: Blockbuster Diet Drug Likely Won't be Sold in Europe



9/21/2012 7:36:42 AM

Vivus stock slumped more than 10% this morning after the company said its weight-loss drug will likely be denied approval in Europe. The European Medicines Agency will make a formal decision on the drug, Qsiva, at a meeting next month. But initial comments from the organization make Qsiva’s future seem clouded. Vivus will have the opportunity to resubmit the medicine or appeal. “We await the official decision and the formal report which should provide us specifics on any additional requirements leading to the approval of Qsiva in Europe,” said Vivus President Peter Tam. “We will work … to address the Committee’s concerns. VIVUS is committed to making this important medication available to obese patients in Europe.”

Read at Forbes
Read at RTT News
Read at Reuters
Read at Street Insider
Read at Market Watch
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES